Equity financing · Biotech

MicroCyto raises nearly ¥300 million for methanol-based biomanufacturing

The January equity financing will advance bulk amino acids and bio-based materials made from non-food feedstocks.

MicroCyto announced nearly ¥300 million in new equity financing on January 4, 2026. Beijing New Materials Industry Investment Fund, Beijing Medical and Health Care Industry Investment Fund, CCB Financial Asset Investment and Zhongguancun Capital participated.

The company will use the funding to develop methanol-based production pipelines for bulk amino acids and bio-based material monomers. It has developed microbial strains that use methanol, aiming to reduce the industry’s reliance on food-derived feedstocks.

MicroCyto has also developed nutrition ingredients including allulose, lutein and mannitol. Its allulose fermentation process received Chinese regulatory approval in July 2025, and the company entered a commercial partnership with Cargill that August.

Use of funds

Develop methanol-based biomanufacturing pipelines for bulk amino acids and bio-based material monomers.

Funding history

Equity financing · This round~CN¥300M

Sources

  1. MicroCyto january financing36kr.com · Jan 4, 2026